Potential impact of Helicobacter pylori-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis.

[1]  E. Cholongitas,et al.  Galectin-3 is associated with glomerular filtration rate and outcome in patients with stable decompensated cirrhosis. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  J. Kountouras,et al.  Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy , 2019, Helicobacter.

[3]  M. Doulberis,et al.  Potential Impact of Helicobacter Pylori on Hepatic Encephalopathy Pathophysiology , 2018, Digestive Diseases and Sciences.

[4]  E. Kazakos,et al.  A potential impact of Helicobacter pylori-related galectin-3 in neurodegeneration , 2018, Neurochemistry International.

[5]  L. Lavra,et al.  Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z , 2018, International journal of molecular sciences.

[6]  J. Kountouras,et al.  Helicobacter pylori‐related chronic hepatitis C infection and the risk for cardiovascular disease , 2017, Liver international (Print).

[7]  C. Thongprayoon,et al.  Association between Helicobacter pylori and end-stage renal disease: A meta-analysis , 2017, World journal of gastroenterology.

[8]  E. Dardiotis,et al.  Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. , 2017, International journal of cardiology.

[9]  G. Daikos,et al.  Systemic levels of human β-defensin 1 are elevated in patients with cirrhosis , 2016, Annals of gastroenterology.

[10]  J. Kountouras,et al.  Helicobacter pylori infection and liver cirrhosis: possible association with hepatic encephalopathy and/or post-hepatic encephalopathy cognitive impairment in patients with portal hypertension , 2014, Annals of gastroenterology.